CA2279134A1 - Strategie nouvelle pour les vaccins therapeutiques a base de glucides - Google Patents
Strategie nouvelle pour les vaccins therapeutiques a base de glucides Download PDFInfo
- Publication number
- CA2279134A1 CA2279134A1 CA002279134A CA2279134A CA2279134A1 CA 2279134 A1 CA2279134 A1 CA 2279134A1 CA 002279134 A CA002279134 A CA 002279134A CA 2279134 A CA2279134 A CA 2279134A CA 2279134 A1 CA2279134 A1 CA 2279134A1
- Authority
- CA
- Canada
- Prior art keywords
- sialic acid
- cells
- modified
- alpha
- polysialic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001720 carbohydrates Chemical class 0.000 title description 6
- 229940021747 therapeutic vaccine Drugs 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 59
- 239000002253 acid Substances 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 239000002243 precursor Substances 0.000 claims abstract description 24
- 125000005629 sialic acid group Chemical group 0.000 claims abstract description 24
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 16
- 239000003550 marker Substances 0.000 claims abstract description 13
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 239000002458 cell surface marker Substances 0.000 claims abstract description 10
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 230000002163 immunogen Effects 0.000 claims abstract description 8
- 230000003834 intracellular effect Effects 0.000 claims abstract description 4
- 230000004044 response Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 17
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical group N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 238000010348 incorporation Methods 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000009877 rendering Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 17
- 102000036639 antigens Human genes 0.000 abstract description 17
- 108091007433 antigens Proteins 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000006181 N-acylation Effects 0.000 abstract description 2
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108010060123 Conjugate Vaccines Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229940031670 conjugate vaccine Drugs 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000003047 N-acetyl group Chemical group 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- -1 propionyl anhydride Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710169972 Menin Proteins 0.000 description 2
- 102100030550 Menin Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QKPLRMLTKYXDST-OHXGPSCHSA-N (3s,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-OHXGPSCHSA-N 0.000 description 1
- JLJZRAUDCHWQPS-NYONGVCJSA-N 4-oxo-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]pentanamide Chemical compound CC(=O)CCC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O JLJZRAUDCHWQPS-NYONGVCJSA-N 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000617590 Escherichia coli K1 Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000006289 propionylation Effects 0.000 description 1
- 238000010515 propionylation reaction Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002279134A CA2279134A1 (fr) | 1999-07-29 | 1999-07-29 | Strategie nouvelle pour les vaccins therapeutiques a base de glucides |
| AU64200/00A AU6420000A (en) | 1999-07-29 | 2000-07-28 | Novel strategy for carbohydrate-based therapeutic vaccines |
| PCT/CA2000/000886 WO2001009298A2 (fr) | 1999-07-29 | 2000-07-28 | Nouvelles strategies pour des vaccins therapeutiques a base de glucides |
| MXPA02000958A MXPA02000958A (es) | 1999-07-29 | 2000-07-28 | Estrategia novedosa para vacunas terapeuticas basadas en hidratos de carbono. |
| IL14777600A IL147776A0 (en) | 1999-07-29 | 2000-07-28 | Process for modifying sialic acid units of cells |
| EP00951149A EP1198244A2 (fr) | 1999-07-29 | 2000-07-28 | Strategie pour des vaccins therapeutiques a base de glucides |
| CA002380488A CA2380488A1 (fr) | 1999-07-29 | 2000-07-28 | Nouvelles strategies pour des vaccins therapeutiques a base de glucides |
| JP2001514090A JP2003506034A (ja) | 1999-07-29 | 2000-07-28 | 糖鎖に基づく治療ワクチンのための新規ストラテジー |
| ZA200200731A ZA200200731B (en) | 1999-07-29 | 2002-01-28 | Novel strategy for carbohydrate-based therapeutic vaccines. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002279134A CA2279134A1 (fr) | 1999-07-29 | 1999-07-29 | Strategie nouvelle pour les vaccins therapeutiques a base de glucides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2279134A1 true CA2279134A1 (fr) | 2001-01-29 |
Family
ID=4163882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002279134A Abandoned CA2279134A1 (fr) | 1999-07-29 | 1999-07-29 | Strategie nouvelle pour les vaccins therapeutiques a base de glucides |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1198244A2 (fr) |
| JP (1) | JP2003506034A (fr) |
| AU (1) | AU6420000A (fr) |
| CA (1) | CA2279134A1 (fr) |
| IL (1) | IL147776A0 (fr) |
| MX (1) | MXPA02000958A (fr) |
| WO (1) | WO2001009298A2 (fr) |
| ZA (1) | ZA200200731B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2417574A1 (fr) * | 2000-07-28 | 2002-02-07 | National Research Council Of Canada | Vaccins a base d'acide sialique modifie |
| EP1293212A1 (fr) * | 2001-08-21 | 2003-03-19 | National Research Council Of Canada | Vaccin contre le cancer comprenant des cellules cancéreuses entières ayant un acide sialique modifié |
| WO2006002402A2 (fr) * | 2004-06-23 | 2006-01-05 | Children's Hospital & Research Center At Oakland | Derives de polysaccharide et leur utilisation pour induire une reponse immunitaire |
| US8148335B2 (en) | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
| MX2008008185A (es) * | 2005-12-23 | 2008-11-14 | Childrens Hosp & Res Ct Oak | Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer. |
| EP2007427A4 (fr) | 2006-04-11 | 2012-04-04 | Yeda Res & Dev | Vaccins ameliores comprenant des supports peptidiques multimeres derives de la hsp60 |
| JP5702600B2 (ja) | 2007-07-03 | 2015-04-15 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | オリゴシアル酸誘導体、製造方法および免疫学的使用 |
| EP2183261A4 (fr) | 2007-07-03 | 2010-09-15 | Childrens Hosp & Res Ct Oak | Dérivés d'acide polysialique, procédés de production, et utilisations pour améliorer la production et le ciblage d'antigènes de cancers |
| CA2692419C (fr) | 2007-07-03 | 2017-12-05 | Children's Hospital & Research Center At Oakland | Inhibiteurs de l'acide polysialique de-n-acetylase et procedes pour leur utilisation |
| US8640245B2 (en) | 2010-12-24 | 2014-01-28 | Kaspersky Lab, Zao | Optimization of anti-malware processing by automated correction of detection rules |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102663A (en) * | 1988-10-18 | 1992-04-07 | Sloan-Kettering Instutute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3 |
| US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
-
1999
- 1999-07-29 CA CA002279134A patent/CA2279134A1/fr not_active Abandoned
-
2000
- 2000-07-28 IL IL14777600A patent/IL147776A0/xx unknown
- 2000-07-28 AU AU64200/00A patent/AU6420000A/en not_active Abandoned
- 2000-07-28 WO PCT/CA2000/000886 patent/WO2001009298A2/fr not_active Application Discontinuation
- 2000-07-28 MX MXPA02000958A patent/MXPA02000958A/es unknown
- 2000-07-28 JP JP2001514090A patent/JP2003506034A/ja active Pending
- 2000-07-28 EP EP00951149A patent/EP1198244A2/fr not_active Withdrawn
-
2002
- 2002-01-28 ZA ZA200200731A patent/ZA200200731B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6420000A (en) | 2001-02-19 |
| WO2001009298A3 (fr) | 2001-08-23 |
| JP2003506034A (ja) | 2003-02-18 |
| WO2001009298A2 (fr) | 2001-02-08 |
| IL147776A0 (en) | 2002-08-14 |
| MXPA02000958A (es) | 2003-07-21 |
| EP1198244A2 (fr) | 2002-04-24 |
| ZA200200731B (en) | 2003-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102245204B (zh) | α-半乳糖基神经酰胺类似物以及它们作为免疫疗法、佐剂和抗病毒剂、抗细菌剂和抗癌剂的应用 | |
| JP5555230B2 (ja) | β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物 | |
| EP0831898B1 (fr) | Vaccins aux polysaccharides meningococciques conjugues modifies | |
| CA2941174C (fr) | Nouveaux polysaccharides immunogenes issus de clostridium difficile | |
| AU2011200618B2 (en) | Immunologically Active Compositions | |
| US20140378669A1 (en) | Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid | |
| CA2279134A1 (fr) | Strategie nouvelle pour les vaccins therapeutiques a base de glucides | |
| KR20030096369A (ko) | 저분자량 하이알루론산과 폴리펩티드 독소의 면역원성접합체 | |
| JPH04507244A (ja) | リピドａ類似体／免疫原性担体コンジュゲートおよびそのワクチンとしての使用 | |
| US20040009195A1 (en) | Modified sialic acid vaccines | |
| CA2128212A1 (fr) | Vaccin conjugue lps-toxine du cholera detoxifie pour la prevention du cholera | |
| JPH07502011A (ja) | 免疫抑制性および寛容原性のオリゴ糖誘導体 | |
| CA2380488A1 (fr) | Nouvelles strategies pour des vaccins therapeutiques a base de glucides | |
| Mel'nikov et al. | Suppression of growth and metastasizing of T-cell lymphoma in mice infected with american trypanosomiasis at different stages of experimental infection | |
| Pequegnat | Polysaccharide Vaccines for Enteric Pathogens: The Next Generation Multivalent Diarrhea Vaccine | |
| RU2671473C2 (ru) | Вакцина против кампилобактериоза | |
| CN113817677B (zh) | 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途 | |
| US20220117997A1 (en) | Polysaccharide compositions for use in treating filariasis | |
| AU665126B2 (en) | Anti-inflammatory, tolerogenic and immunostimulatory properties of carbohydrate binding-proteins | |
| CN117467001A (zh) | A型产气荚膜梭菌抗毒素血清的制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |